acut posit inotrop intervent phosphodiesteras inhibitor phosphodiesteras inhibitor select camp-specif cardiac vascular pde iii new group agent treatment heart failur present clinic shortterm intraven use research intraven amrinon milrinon fda amrinon avail gener clinic use select phosphodiesteras inhibit benefici action posit inotropi peripher vasodil result cardiac vascular muscl concentr intracellular camp ionic calcium addit posit lusitrop action enhanc cardiac relax beta-adrenerg agonist activ inhibit sodium-potassium atpas agent magnitud hemodynam improv cardiac glycosid compar intraven catecholamin dobutamin differ pharmacodynam profil pde inhibitor addit effect cardiac glycosid complementari synergist action catecholamin favor effect coronari hemodynam result continu enthusiasm short-term intraven use amrinon milrinon set acut heart failur systol dysfunct myocardi infarct open heart surgeri infecti toxic myocard heart failur right ventricular systol dysfunct patient sever heart failur cardiac transplant initi treatment intraven bolu mainten infus prompt increas stroke volum cardiac output simultan reduct right ventricular fill pressur system vascular resist 